Gordon, M. S., Nemunaitis, J. J., Ramanathan, R. K., Sledge, G. W., Wang, L., Fan, X., … Strickler, J. H. (2016). Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors. In Journal of Clinical Oncology (Vol. 34, pp. 2507–2507). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.2507

Gordon, Michael S., John J. Nemunaitis, Ramesh K. Ramanathan, George W. Sledge, Lan Wang, Xiaolin Fan, Monica Motwani, et al. “Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.” In Journal of Clinical Oncology, 34:2507–2507. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2507.

Gordon MS, Nemunaitis JJ, Ramanathan RK, Sledge GW, Wang L, Fan X, et al. Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 2507–2507.

Gordon, Michael S., et al. “Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 2507–2507. Crossref, doi:10.1200/jco.2016.34.15_suppl.2507.

Gordon MS, Nemunaitis JJ, Ramanathan RK, Sledge GW, Wang L, Fan X, Motwani M, Wong S, Morgan-Lappe S, Iyer S, Naumovski L, Strickler JH. Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 2507–2507.